You are not logged in.
Openly accessible

A new era in the treatment of multiple sclerosis

Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeanette, Macdonell, Richard A., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith M., Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., King, John, McCombe, Pamela A., Pollard, John D. and Willoughby, Ernest 2015, A new era in the treatment of multiple sclerosis, Medical journal of Australia, vol. 203, no. 3, pp. 139-141.

Attached Files
Name Description MIMEType Size Downloads
broadley-anewera-2015.pdf Published version application/pdf 1.66MB 11

Title A new era in the treatment of multiple sclerosis
Author(s) Broadley, Simon A.
Barnett, Michael H.
Boggild, Mike
Brew, Bruce J.
Butzkueven, Helmut
Heard, Robert
Hodgkinson, Suzanne
Kermode, Allan G.
Lechner-Scott, Jeanette
Macdonell, Richard A.
Marriott, Mark
Mason, Deborah F.
Parratt, John
Reddel, Stephen W.
Shaw, Cameron P.
Slee, Mark
Spies, Judith M.
Taylor, Bruce V.
Carroll, William M.
Kilpatrick, Trevor J.
King, John
McCombe, Pamela A.
Pollard, John D.
Willoughby, Ernest
Journal name Medical journal of Australia
Volume number 203
Issue number 3
Start page 139
End page 141
Total pages 3
Publisher Australasian Medical Publishing
Place of publication Sydney, N.S.W.
Publication date 2015-08-03
ISSN 1326-5377
Keyword(s) Disease Management
Humans
Immunosppressive Agents
Multiple Sclerosis
Summary Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
Language eng
Field of Research 1117 Public Health And Health Services
1103 Clinical Sciences
110399 Clinical Sciences not elsewhere classified
Socio Economic Objective 920111 Nervous System and Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Australasian Medical Publishing
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30080418

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 3 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 103 Abstract Views, 12 File Downloads  -  Detailed Statistics
Created: Tue, 05 Jan 2016, 13:55:45 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.